CME Available: https://auau.auanet.org/node/35405

Moderator: Todd Morgan, MD

Panelists: Maria Carlo, MD; Elisabeth Heath, MD, FACP; Brian Helfand, MD

At the conclusion of this activity, participants will be able to:

1. Review recommended criteria for genetic testing of prostate cancer patients, explain how to counsel patients about genetic testing, and how to order and interpret these tests.

2. Explain how mutations in DNA damage repair genes can lead to the development of aggressive prostate cancer and the implications for treatment decisions.

3. Describe the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition for cancer treatment.

4. Discuss clinical trial data assessing the efficacy of PARP inhibitors in advanced prostate cancer, including patient populations and clinical outcomes for each trial.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck